Immunovia (IMMNOV.ST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $75M

Market Cap: $14.5MFounded: 2007HQ: Lund, Sweden

Sector Ranking#103 in Diagnostics & Precision Medicine #113 in Oncology (General)

Overview

Immunovia is a lean, focused diagnostics company dedicated to improving the abysmal survival rate of pancreatic cancer through early detection. Its core achievement is the development of PancreaSure, a blood test demonstrating 78% sensitivity and 94% specificity for early-stage disease in validation studies. The company's strategy is to execute a capital-efficient commercial launch in the U.S. in late 2025, targeting the significant unmet need in surveillance for high-risk populations, thereby aiming to create substantial shareholder value.

OncologyPancreatic Cancer

Technology Platform

A proprietary blood-based proteomic assay utilizing the ELISA platform to detect a signature of protein biomarkers associated with early-stage pancreatic ductal adenocarcinoma (PDAC).

Funding History

3

Total raised:$75M

IPO$40MUndisclosedMar 19, 2020

Series B$25MUndisclosedSep 15, 2017

Series A$10MUndisclosedJun 15, 2015

Opportunities

The primary opportunity is a multi-billion dollar U.S.

market for surveillance of high-risk individuals, where current methods are invasive and costly.

Successful execution could position PancreaSure as a new standard of care, with potential for expansion into adjacent indications or broader screening in the long term.

Risk Factors

Key risks include failure to execute the U.S.

commercial launch, delays or denials in securing insurance reimbursement, competition from emerging liquid biopsy tests, and the possibility that real-world test performance may not match clinical study results.

Competitive Landscape

Competition includes other liquid biopsy firms (e.g., Bluestar Genomics, Guardant Health pipeline) and the standard of care (MRI/EUS). Immunovia differentiates through its specific focus on early detection in a high-risk screening context, compelling performance data, and a capital-efficient LDT commercial model.